{"a":[{"_":"Vertex’s latest autoimmune TCE play involves $28M upfront to AbCellera","$":{"href":"/biotech/vertexs-latest-autoimmune-tce-play-involves-28m-upfront-abcellera","hreflang":"en"}}]}

Summary

Vertex Pharmaceuticals entered into a collaboration with AbCellera, paying $28 million upfront to develop T-cell engager therapeutics for autoimmune conditions, marking AbCellera's second client for its TCE platform.